阿维A与氨甲蝶呤治疗重度斑块型银屑病的疗效

Efficacy of Acitretin A and Methotrexate in severe plaque psoriasis

目的对比阿维A与氨甲蝶呤对重度斑块型银屑病的治疗效果。方法选取2016年9月至2018年9月本院收治的重度斑块型银屑病患者64例作为研究对象,根据病历单双号分为阿维A组(接受阿维A口服治疗)和氨甲蝶呤组(接受氨甲蝶呤口服治疗),每组32例。统计并比较两组治疗效果以及药物不良反应发生情况。结果治疗后,两组银屑病面积评分、银屑病严重度评分较治疗前均下降(P<0.05),但两组银屑病面积评分、银屑病严重度评分差异无统计学意义;阿维A组治疗总有效率为96.88%,氨甲蝶呤组治疗总有效率为93.75%,组间比较差异无统计学意义;阿维A组药物不良反应发生率为21.88%,氨甲蝶呤组药物不良反应发生率为18.75%,两组药物不良反应均不严重,组间比较差异无统计学意义。结论阿维A与氨甲蝶呤都可安全、有效地治疗重度斑块型银屑病,且疗效、安全性相当。

Objective To compare the curative effect of Acitretin A and Methotrexate in severe plaque psoriasis patients.Methods 64 severe plaque psoriasis patients treated from September 2016 to September 2018 in our hospital were selected and assigned to Acitretin A group(oral medication of Acitretin)and Methotrexate group(oral medication of Methotrexate),with 32 cases in each group.The therapeutic effect and adverse event rate were compared.Results After treatment,the psoriasis area and severity scores for two groups were dramatically reduced(P<0.05).After treatment,related scores between groups were not significantly different.The total effective rate in Acitretin A group(96.88%)and Methotrexate group(93.75%)was not significantly difference.The adverse event rate in Acitretin A group(21.88%)and Methotrexate group(18.75%)was not significantly difference.Conclusion Both of Acitretin A and Methotrexate are clinically proven to be effective and safe.